Cargando…
Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections
In recent years, there has been an increase in deaths due to infectious diseases, most notably in the context of viral respiratory pathogens. Consequently, the focus has shifted in the search for new therapies, with attention being drawn to the use of nanoparticles in mRNA vaccines for targeted deli...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146241/ https://www.ncbi.nlm.nih.gov/pubmed/37111613 http://dx.doi.org/10.3390/pharmaceutics15041127 |
_version_ | 1785034533831180288 |
---|---|
author | Hajiaghapour Asr, Mena Dayani, Fatemeh Saedi Segherloo, Fatemeh Kamedi, Ali Neill, Andrew O’ MacLoughlin, Ronan Doroudian, Mohammad |
author_facet | Hajiaghapour Asr, Mena Dayani, Fatemeh Saedi Segherloo, Fatemeh Kamedi, Ali Neill, Andrew O’ MacLoughlin, Ronan Doroudian, Mohammad |
author_sort | Hajiaghapour Asr, Mena |
collection | PubMed |
description | In recent years, there has been an increase in deaths due to infectious diseases, most notably in the context of viral respiratory pathogens. Consequently, the focus has shifted in the search for new therapies, with attention being drawn to the use of nanoparticles in mRNA vaccines for targeted delivery to improve the efficacy of these vaccines. Notably, mRNA vaccine technologies denote as a new era in vaccination due to their rapid, potentially inexpensive, and scalable development. Although they do not pose a risk of integration into the genome and are not produced from infectious elements, they do pose challenges, including exposing naked mRNAs to extracellular endonucleases. Therefore, with the development of nanotechnology, we can further improve their efficacy. Nanoparticles, with their nanometer dimensions, move more freely in the body and, due to their small size, have unique physical and chemical properties. The best candidates for vaccine mRNA transfer are lipid nanoparticles (LNPs), which are stable and biocompatible and contain four components: cationic lipids, ionizable lipids, polyethylene glycols (PEGs), and cholesterol, which are used to facilitate cytoplasmic mRNA delivery. In this article, the components and delivery system of mRNA-LNP vaccines against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus are reviewed. Moreover, we provide a succinct overview of current challenges and potential future directions in the field. |
format | Online Article Text |
id | pubmed-10146241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101462412023-04-29 Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections Hajiaghapour Asr, Mena Dayani, Fatemeh Saedi Segherloo, Fatemeh Kamedi, Ali Neill, Andrew O’ MacLoughlin, Ronan Doroudian, Mohammad Pharmaceutics Review In recent years, there has been an increase in deaths due to infectious diseases, most notably in the context of viral respiratory pathogens. Consequently, the focus has shifted in the search for new therapies, with attention being drawn to the use of nanoparticles in mRNA vaccines for targeted delivery to improve the efficacy of these vaccines. Notably, mRNA vaccine technologies denote as a new era in vaccination due to their rapid, potentially inexpensive, and scalable development. Although they do not pose a risk of integration into the genome and are not produced from infectious elements, they do pose challenges, including exposing naked mRNAs to extracellular endonucleases. Therefore, with the development of nanotechnology, we can further improve their efficacy. Nanoparticles, with their nanometer dimensions, move more freely in the body and, due to their small size, have unique physical and chemical properties. The best candidates for vaccine mRNA transfer are lipid nanoparticles (LNPs), which are stable and biocompatible and contain four components: cationic lipids, ionizable lipids, polyethylene glycols (PEGs), and cholesterol, which are used to facilitate cytoplasmic mRNA delivery. In this article, the components and delivery system of mRNA-LNP vaccines against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus are reviewed. Moreover, we provide a succinct overview of current challenges and potential future directions in the field. MDPI 2023-04-03 /pmc/articles/PMC10146241/ /pubmed/37111613 http://dx.doi.org/10.3390/pharmaceutics15041127 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hajiaghapour Asr, Mena Dayani, Fatemeh Saedi Segherloo, Fatemeh Kamedi, Ali Neill, Andrew O’ MacLoughlin, Ronan Doroudian, Mohammad Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections |
title | Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections |
title_full | Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections |
title_fullStr | Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections |
title_full_unstemmed | Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections |
title_short | Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections |
title_sort | lipid nanoparticles as promising carriers for mrna vaccines for viral lung infections |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146241/ https://www.ncbi.nlm.nih.gov/pubmed/37111613 http://dx.doi.org/10.3390/pharmaceutics15041127 |
work_keys_str_mv | AT hajiaghapourasrmena lipidnanoparticlesaspromisingcarriersformrnavaccinesforvirallunginfections AT dayanifatemeh lipidnanoparticlesaspromisingcarriersformrnavaccinesforvirallunginfections AT saedisegherloofatemeh lipidnanoparticlesaspromisingcarriersformrnavaccinesforvirallunginfections AT kamediali lipidnanoparticlesaspromisingcarriersformrnavaccinesforvirallunginfections AT neillandrewo lipidnanoparticlesaspromisingcarriersformrnavaccinesforvirallunginfections AT macloughlinronan lipidnanoparticlesaspromisingcarriersformrnavaccinesforvirallunginfections AT doroudianmohammad lipidnanoparticlesaspromisingcarriersformrnavaccinesforvirallunginfections |